A double-blind, randomised, placebo-controlled trial evaluating the effect of BI 655064 administered as sub-cutaneous injections, on renal response after one year of treatment, in patients with active lupus nephritis
A study for patients with Lupus Nephritis using the study drug BI 655064.
Sponsor: Boehringer Ingelheim
Enrolling: Male and Female Patients
Study Length: 60 Weeks
Clinic Visits: 18
IRB Number: AAAQ6365
U.S. Govt. ID: NCT02770170
Contact: Anca Askanase MD MPH: 212-305-0856 / ada20@cumc.columbia.edu
Additional Study Information: This study is for men and women who have been diagnosed with Lupus Nephritis. In this study, doctors will evaluate the effectiveness of the investigational medication administered as sub-cutaneous injections for Lupus Nephritis over a 52 week period. All study-related visits, tests, and medications will be provided to you at no cost.
This study is closed
Anca Askanase, MD, MPH
Do You Qualify?
Have you been diagnosed with Lupus Erythematosus (SLE)? Yes No
Have you been recently diagnosed with Lupus Nephritis and received a renal biopsy within the last three months? Yes No
Should you qualify, would you be ready and able to use highly effective methods of birth control? Yes No
Are you pregnant, nursing, or plan to become pregnant while in the trial? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Anca Askanase MD MPH